Lack of an association between gallstone disease and bilirubin levels with risk of colorectal cancer: a Mendelian randomisation analysis.


Journal

British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635

Informations de publication

Date de publication:
03 2021
Historique:
received: 14 05 2020
accepted: 25 11 2020
revised: 09 10 2020
pubmed: 9 1 2021
medline: 28 9 2021
entrez: 8 1 2021
Statut: ppublish

Résumé

Epidemiological studies of the relationship between gallstone disease and circulating levels of bilirubin with risk of developing colorectal cancer (CRC) have been inconsistent. To address possible confounding and reverse causation, we examine the relationship between these potential risk factors and CRC using Mendelian randomisation (MR). We used two-sample MR to examine the relationship between genetic liability to gallstone disease and circulating levels of bilirubin with CRC in 26,397 patients and 41,481 controls. We calculated the odds ratio per genetically predicted SD unit increase in log bilirubin levels (OR No association between either gallstone disease (P value = 0.60) or circulating levels of bilirubin (OR Despite the large scale of this study, we found no evidence for a causal relationship between either circulating levels of bilirubin or gallstone disease with risk of developing CRC. While the magnitude of effect suggested by some observational studies can confidently be excluded, we cannot exclude the possibility of smaller effect sizes and non-linear relationships.

Sections du résumé

BACKGROUND
Epidemiological studies of the relationship between gallstone disease and circulating levels of bilirubin with risk of developing colorectal cancer (CRC) have been inconsistent. To address possible confounding and reverse causation, we examine the relationship between these potential risk factors and CRC using Mendelian randomisation (MR).
METHODS
We used two-sample MR to examine the relationship between genetic liability to gallstone disease and circulating levels of bilirubin with CRC in 26,397 patients and 41,481 controls. We calculated the odds ratio per genetically predicted SD unit increase in log bilirubin levels (OR
RESULTS
No association between either gallstone disease (P value = 0.60) or circulating levels of bilirubin (OR
CONCLUSIONS
Despite the large scale of this study, we found no evidence for a causal relationship between either circulating levels of bilirubin or gallstone disease with risk of developing CRC. While the magnitude of effect suggested by some observational studies can confidently be excluded, we cannot exclude the possibility of smaller effect sizes and non-linear relationships.

Identifiants

pubmed: 33414539
doi: 10.1038/s41416-020-01211-x
pii: 10.1038/s41416-020-01211-x
pmc: PMC7961009
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1169-1174

Subventions

Organisme : Cancer Research UK
ID : 12076
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U24 CA074783
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074794
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167551
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA097735
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167551
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074783
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_00007/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_U127527198
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U127527198
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K018647/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U24 CA097735
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074794
Pays : United States

Références

Chen, Y.-K., Yeh, J.-H., Lin, C.-L., Peng, C.-L., Sung, F.-C., Hwang, M. et al. Cancer risk in patients with cholelithiasis and after cholecystectomy: a nationwide cohort study. J. Gastroenterol. 49, 923–931 (2014).
pubmed: 23807230 doi: 10.1007/s00535-013-0846-6
Ward, H. A., Murphy, N., Weiderpass, E., Leitzmann, M. F., Aglago, E., Gunter, M. J. et al. Gallstones and incident colorectal cancer in a large pan‐European cohort study. Int J. Cancer 145, 1510–1516 (2019).
pubmed: 30585640 doi: 10.1002/ijc.32090
World Cancer Research Fund, American Institute for Cancer Research. Diet, nutrition, physical activity and colorectal cancer. https://www.wcrf.org/sites/default/files/Colorectal-Cancer-2017-Report.pdf (2018).
Wang, F., Wang, J., Li, Y., Yuan, J., Yao, P., Wei, S. et al. Gallstone disease and type 2 diabetes risk: a mendelian randomization study. Hepatology 70, 610–620 (2019).
pubmed: 30515881 doi: 10.1002/hep.30403
Temme, E. H. M., Zhang, J., Schouten, E. G. & Kesteloot, H. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 12, 887–894 (2001).
pubmed: 11808707 doi: 10.1023/A:1013794407325
Zucker, S. D., Horn, P. S. & Sherman, K. E. Serum bilirubin levels in the US population: gender effect and inverse correlation with colorectal cancer. Hepatology 40, 827–835 (2004).
pubmed: 15382174 doi: 10.1002/hep.1840400412
Ioannou, G. N., Liou, I. W. & Weiss, N. S. Serum bilirubin and colorectal cancer risk: a population‐based cohort study. Aliment Pharm. Ther. 23, 1637–1642 (2006).
doi: 10.1111/j.1365-2036.2006.02939.x
Stender, S., Frikke-Schmidt, R., Nordestgaard, B. G. & Tybjærg-Hansen, A. Extreme bilirubin levels as a causal risk factors for sympotomatic gallstone disease. JAMA Intern. Med. 173, 1222–1228 (2013).
pubmed: 23753274 doi: 10.1001/jamainternmed.2013.6465
Kühn, T., Sookthai, D., Graf, M. E., Schübel, R., Freisling, H., Johnson, T. et al. Albumin, bilirubin, uric acid and cancer risk: results from a prospective population-based study. Br. J. Cancer 117, 1572–1579 (2017).
pubmed: 28898231 pmcid: 5680462 doi: 10.1038/bjc.2017.313
Buch, S., Schafmayer, C., Völzke, H., Seeger, M., Miquel, J. F., Sookoian, S. C. et al. Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition. Gastroenterology 139, 1942–1951 (2010).
pubmed: 20837016 doi: 10.1053/j.gastro.2010.09.003
Stocker, R., Yamamoto, Y., McDonagh, A. F., Glazer, A. N. & Ames, B. N. Bilirubin is an antioxidant of possible physiological importance. Science 235, 1043–1046 (1987).
pubmed: 3029864 doi: 10.1126/science.3029864
Rao, P., Suzuki, R., Mizobuchi, S., Yamaguchi, T. & Sasaguri, S. Bilirubin exhibits a novel anti-cancer effect on human adenocarcinoma. Biochem Biophys. Res. Commun. 342, 1279–1283 (2006).
pubmed: 16516158 doi: 10.1016/j.bbrc.2006.02.074
Vítek, L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front. Pharm. 3, 55 (2012).
doi: 10.3389/fphar.2012.00055
Didelez, V. & Sheehan, N. Mendelian randomization as an instrumental variable approach to causal inference. Stat. Methods Med. Res. 16, 309–330 (2007).
pubmed: 17715159 doi: 10.1177/0962280206077743
Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet. Epidemiol. 37, 658–665 (2013).
pubmed: 24114802 pmcid: 4377079 doi: 10.1002/gepi.21758
Haycock, P. C., Burgess, S., Wade, K. H., Bowden, J., Relton, C. & Davey Smith, G. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. Am. J. Clin. Nutr. 103, 965–978 (2016).
pubmed: 26961927 pmcid: 4807699 doi: 10.3945/ajcn.115.118216
Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D. et al. The MR-base platform supports systematic causal inference across the human phenome. eLife 7, e34408 (2018).
pubmed: 29846171 pmcid: 5976434 doi: 10.7554/eLife.34408
Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 362, k601 (2018).
pubmed: 30002074 pmcid: 6041728 doi: 10.1136/bmj.k601
Burgess, S., Smith, G. D., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M. et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res. 4, 186 (2019). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384151/ , Published online 2020.
Brumpton, B., Sanderson, E., Heilbron, K., Hartwig, F. P., Harrison, S., Vie, G. Å. et al. Avoiding dynastic, assortative mating, and population stratification biases in Mendelian randomization through within-family analyses. Nat. Commun. 11, 3519 (2020).
pubmed: 32665587 pmcid: 7360778 doi: 10.1038/s41467-020-17117-4
Gudbjartsson, D. F., Helgason, H., Gudjonsson, S. A., Zink, F., Oddson, A., Gylfason, A. et al. Large-scale whole-genome sequencing of the Icelandic population. Nat. Genet. 47, 435–444 (2015).
pubmed: 25807286 doi: 10.1038/ng.3247
Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203–209 (2018).
pubmed: 30305743 pmcid: 6786975 doi: 10.1038/s41586-018-0579-z
Ferkingstad, E., Oddsson, A., Gretarsdottir, S., Benonisdottir, S., Thorleifsson, G., Deaton, A. M. et al. Genome-wide association meta-analysis yields 20 loci associated with gallstone disease. Nat. Commun. 9, 5101 (2018).
pubmed: 30504769 pmcid: 6269469 doi: 10.1038/s41467-018-07460-y
Johnson, A. D., Kavousi, M., Smith, A. V., Chen, M.-H., Dehghan, A., Aspelund, T. et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum. Mol. Genet. 18, 2700–2710 (2009).
pubmed: 19414484 pmcid: 2701336 doi: 10.1093/hmg/ddp202
Borodulin, K., Tolonen, H., Jousilahti, P., Jula, A., Koskinen, S., Kuulasmaa, K. et al. Cohort profile: the national FINRISK study. Int. J. Epidemiol. 47, 696–696i (2018).
pubmed: 29165699 doi: 10.1093/ije/dyx239
Law, P. J., Timofeeva, M., Fernandez-Rozadilla, C., Broderick, P., Studd, J., Fernandez-Tajes, J. et al. Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nat. Commun. 10, 2154 (2019).
pubmed: 31089142 pmcid: 6517433 doi: 10.1038/s41467-019-09775-w
Burgess, S. & Thompson, S. G. Assumptions for causal inference. in Mendelian Randomization: Methods for Using Genetic Variants in Causal Estimation, 1st edn. (eds Burgess, S., Thompson, S. G.) 25–44 (Chapman & Hall/CRC Press, New York, 2015).
Bowden, J., Del Greco, M. F., Minelli, C., Davey Smith, G., Sheehan, N. & Thompson, J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat. Med. 36, 1783–1802 (2017).
pubmed: 28114746 pmcid: 5434863 doi: 10.1002/sim.7221
Thompson, S. G. & Sharp, S. J. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat. Med. 18, 2693–2708 (1999).
pubmed: 10521860 doi: 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
Didelez, V., Meng, S. & Sheehan, N. A. Assumptions of IV methods for observational epidemiology. Stat. Sci. 25, 22–40 (2010).
doi: 10.1214/09-STS316
Disney-Hogg, L., Cornish, A. J., Sud, A., Law, P. J., Kinnersley, B., Jacobs, D. I. et al. Impact of atopy on risk of glioma: a Mendelian randomisation study. BMC Med. 16, 1–13 (2018).
Richmond, R. C., Davey & Smith, G. Comment on ‘orienting causal relationships between two phenotypes using bidirectional Mendelian randomization’. Int. J. Epidemiol. 48, 907–911 (2019).
pubmed: 31298278 doi: 10.1093/ije/dyz149
Burgess, S. & Labrecque, J. A. Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates. Eur. J. Epidemiol. 33, 947–952 (2018).
pubmed: 30039250 pmcid: 6153517 doi: 10.1007/s10654-018-0424-6
Cochran, W. G. The combination of estimates from different experiments. Biometrics 10, 101–129 (1954).
doi: 10.2307/3001666
Del Greco, M. F., Minelli, C., Sheehan, N. A. & Thompson, J. R. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat. Med. 34, 2926–2940 (2015).
doi: 10.1002/sim.6522
Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ 327, 557–560 (2003).
pubmed: 12958120 pmcid: 192859 doi: 10.1136/bmj.327.7414.557
Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet. Epidemiol. 40, 304–314 (2016).
pubmed: 27061298 pmcid: 4849733 doi: 10.1002/gepi.21965
Hartwig, F. P., Smith, G. D. & Bowden, J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int. J. Epidemiol. 46, 1985–1998 (2017).
pubmed: 29040600 pmcid: 5837715 doi: 10.1093/ije/dyx102
Bowden, J., Smith, G. D. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 44, 512–525 (2015).
pubmed: 26050253 pmcid: 4469799 doi: 10.1093/ije/dyv080
Bowden, J., Fabiola Del Greco, M., Minelli, C., Davey Smith, G., Sheehan, N. A. & Thompson, J. R. Assessing the suitability of summary data for two-sample mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int. J. Epidemiol. 45, 1961–1974 (2016).
pubmed: 27616674 pmcid: 5446088 doi: 10.1093/ije/dyw252
Verbanck, M., Chen, C.-Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat. Genet. 50, 693–698 (2018).
pubmed: 29686387 pmcid: 6083837 doi: 10.1038/s41588-018-0099-7
Brion, M.-J. A., Shakhbazov, K. & Visscher, P. M. mRnd: power calculations for Mendelian randomization. https://cnsgenomics.shinyapps.io/mRnd/ (2020).
Brion, M.-J. A., Shakhbazov, K. & Visscher, P. M. Calculating statistical power in Mendelian randomization studies. Int. J. Epidemiol. 42, 1497–1501 (2013).
pubmed: 24159078 doi: 10.1093/ije/dyt179
Shim, H., Chasman, D. I., Smith, J. D., Mora, S., Ridker, P. M., Nickerson, D. A. et al. A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians. PLoS ONE 10, e0120758 (2015).
pubmed: 25898129 pmcid: 4405269 doi: 10.1371/journal.pone.0120758
Staiger, D. O. & Stock, J. H. Instrumental Variables Regression with Weak Instruments (National Bereau of Economic Research Inc, Cambridge, MA, 1994).
R Core Team. R: A Language and Environment for Statistical Computing. http://www.R-project.org/ (R Core Team, Vienna, Austria, 2020).
Jorgensen, T. & Rafaelsen, S. Gallstones and colorectal cancer–there is a relationship, but it is hardly due to cholecystectomy. Dis. Colon Rectum 35, 24–28 (1992).
pubmed: 1733681 doi: 10.1007/BF02053334
Lawlor, D. A. Comment on ‘two-sample Mendelian randomization: opportunities and challenges’. Int. J. Epidemiol. 45, 908–915 (2016).
pubmed: 27427429 pmcid: 5005949 doi: 10.1093/ije/dyw127

Auteurs

Richard Culliford (R)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK. richard.culliford@icr.ac.uk.

Alex J Cornish (AJ)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

Philip J Law (PJ)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

Susan M Farrington (SM)

Cancer Research UK Edinburgh Centre and Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.

Kimmo Palin (K)

Medicum and Genome-Scale Biology Research Program, Research Programs Units, Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland.

Mark A Jenkins (MA)

Centre for Epidemiology and Biostatistics, University of Melbourne, Melbourne, VIC, Australia.

Graham Casey (G)

Centre for Public Health Genomics, University of Virginia, Virginia, VA, USA.

Michael Hoffmeister (M)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.

Hermann Brenner (H)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
Division of Preventive Oncology, German Cancer Research Center, Heidelberg, Germany.
German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany.

Jenny Chang-Claude (J)

Unit of Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Cancer Epidemiology Group, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg, Hamburg, Germany.

Iva Kirac (I)

Department of Surgical Oncology, University Hospital for Tumours, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia.

Tim Maughan (T)

Department of Oncology, University of Oxford, Oxford, UK.

Stefanie Brezina (S)

Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Andrea Gsur (A)

Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Jeremy P Cheadle (JP)

Institute of Medical Genetics, School of Medicine, Cardiff University, Cardiff, UK.

Lauri A Aaltonen (LA)

Medicum and Genome-Scale Biology Research Program, Research Programs Units, Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland.

Malcom G Dunlop (MG)

Cancer Research UK Edinburgh Centre and Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.

Richard S Houlston (RS)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH